Oncology

SORT BY:     Most Recent      Most Viewed
  • July 1, 2006
    PREVIEW

    Osteonecrosis of the jaw is a recently recognized adverse effect of bisphosphonates, and the problem is one that is particularly difficult to manage when it occurs. According to a systematic...

  • July 1, 2006
    PREVIEW

    The Study of Tamoxifen and Raloxifene (STAR) has shown that while both drugs are effective in reducing the incidence of invasive breast cancer by 50% (17 cases or 2% per group), taking...

  • February 1, 2006
    PREVIEW

    A miracle drug in its own time, tamoxifen is increasingly being replaced by aromatase inhibitors in adjuvant postsurgical management of breast cancer. Drug such as letrozole (Femara—Novartis),...

  • June 1, 2005
    PREVIEW

    A pharmacokinetic–pharmacodynamic model proved useful in predicting the white blood cell (WBC) time course—including nadir day and duration of leukopenia—in 44 patients with advanced breast...

  • January 1, 2005
    PREVIEW

    Bisphosphonates can prevent the osteoporosis that can develop in women being treated for breast cancer with bone-depleting hormonal agents. Researchers are also finding that the drugs can help...

Pages